CR20210059A - Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices - Google Patents
Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devicesInfo
- Publication number
- CR20210059A CR20210059A CR20210059A CR20210059A CR20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical composition
- thrombosis
- treatment
- delivery
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4806—Hydrolases (3) acting on peptide bonds (3.4) from animals other than mammals, e.g. snakes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/12036—Type of occlusion partial occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/1204—Type of occlusion temporary occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12136—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
A pharmaceutical composition and a method of using the pharmaceutical composition for the treatment of thrombosis are provided. The pharmaceutical composition can include a mixture of proteolytic enzymes, and optionally, additional compounds. The pharmaceutical composition can include an antiaggregatory or anti -thrombotic compound, such as <em>Lisini racemici acetylsalicylase</em>. The method can include administering the pharmaceutical composition to a patient in need thereof, including administration of the pharmaceutical composition to a thrombus until the thrombus is dissolved. The method can also include administering one or more balloon catheters to the patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862691319P | 2018-06-28 | 2018-06-28 | |
PCT/US2019/039878 WO2020006444A1 (en) | 2018-06-28 | 2019-06-28 | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210059A true CR20210059A (en) | 2021-12-23 |
Family
ID=68985200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210059A CR20210059A (en) | 2018-06-28 | 2019-06-28 | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3813687A4 (en) |
JP (1) | JP2022525713A (en) |
CN (1) | CN112638289A (en) |
AU (1) | AU2019292557A1 (en) |
BR (1) | BR112021004809A2 (en) |
CA (1) | CA3110779A1 (en) |
CR (1) | CR20210059A (en) |
EA (1) | EA202190494A1 (en) |
WO (1) | WO2020006444A1 (en) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6130527A (en) * | 1984-07-20 | 1986-02-12 | Kao Corp | Thrombolytic agent |
AU7278094A (en) * | 1994-06-07 | 1996-01-04 | M D Serv Europe S.A. | Intravasal thrombolysis |
US6022309A (en) * | 1996-04-24 | 2000-02-08 | The Regents Of The University Of California | Opto-acoustic thrombolysis |
FR2797768B1 (en) * | 1999-09-01 | 2003-06-13 | Ifremer | USE OF A LOW MOLECULAR WEIGHT SULPHATE POLYSACCHARIDE FOR THE PRODUCTION OF A MEDICAMENT ACTIVE AGAINST VASCULAR THROMBOSIS |
DK1406641T3 (en) * | 2001-06-18 | 2009-05-04 | Neptune Technologies & Bioress | Curly extracts for the prevention and / or treatment of cardiovascular diseases |
ES2396964T3 (en) * | 2001-10-01 | 2013-03-01 | Matrizyme Pharma Corporation | Use of collagenase to facilitate the crossing with guide wire of chronic arterial occlusions |
CN1210036C (en) * | 2002-06-18 | 2005-07-13 | 蚌埠丰原医药科技发展有限公司 | Novel usage of Aspirin-DL-Lysine |
SE0303588D0 (en) * | 2003-12-30 | 2003-12-30 | Bioactive Polymers Ab C O Lund | Surface protection of exposed biological tissues |
JP4677557B2 (en) * | 2005-05-11 | 2011-04-27 | 国立大学法人東北大学 | Ultrasonic probe, catheter using the same, and manufacturing method thereof |
EP1726301A1 (en) * | 2005-05-24 | 2006-11-29 | Flamel Technologies | Oral pharmaceutical composition for treating a COX-2 mediated condition |
DE102005042338B4 (en) * | 2005-09-06 | 2007-07-05 | Siemens Ag | catheter device |
AR059012A1 (en) * | 2006-01-13 | 2008-03-05 | Aker Biomarine Asa | EXTRACTS DERIVED FROM KRILL |
EP2663335A1 (en) * | 2011-01-13 | 2013-11-20 | Medestea Internazionale S.p.A. | A composition for the regeneration of atrophic tissues |
US10687832B2 (en) * | 2013-11-18 | 2020-06-23 | Koninklijke Philips N.V. | Methods and devices for thrombus dispersal |
DE202015002060U1 (en) * | 2015-03-17 | 2015-11-25 | Gerhard-Friedrich Horak | Infusion and aspiration catheter (IAC) (catheter for removal of thrombi and application of drugs) |
CN110177527B (en) * | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | Device and method for adjusting insertion depth of needle for medicament delivery |
EP3554611A1 (en) * | 2016-12-13 | 2019-10-23 | Boston Scientific Scimed Inc. | Thrombolysis catheter system |
-
2019
- 2019-06-28 WO PCT/US2019/039878 patent/WO2020006444A1/en unknown
- 2019-06-28 CN CN201980057015.2A patent/CN112638289A/en active Pending
- 2019-06-28 BR BR112021004809-0A patent/BR112021004809A2/en not_active Application Discontinuation
- 2019-06-28 CR CR20210059A patent/CR20210059A/en unknown
- 2019-06-28 CA CA3110779A patent/CA3110779A1/en active Pending
- 2019-06-28 EA EA202190494A patent/EA202190494A1/en unknown
- 2019-06-28 AU AU2019292557A patent/AU2019292557A1/en active Pending
- 2019-06-28 EP EP19824845.2A patent/EP3813687A4/en not_active Withdrawn
- 2019-06-28 JP JP2021517700A patent/JP2022525713A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3813687A4 (en) | 2022-03-23 |
EP3813687A1 (en) | 2021-05-05 |
AU2019292557A1 (en) | 2021-04-01 |
JP2022525713A (en) | 2022-05-19 |
EA202190494A1 (en) | 2021-12-09 |
CN112638289A (en) | 2021-04-09 |
BR112021004809A2 (en) | 2021-06-22 |
WO2020006444A1 (en) | 2020-01-02 |
CA3110779A1 (en) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020007853A (en) | Pharmaceutical compositions for treating cystic fibrosis. | |
MX2021007970A (en) | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof. | |
MX2021004707A (en) | New anthelmintic compounds. | |
CR20190503A (en) | Ask1 inhibitor compounds and uses thereof | |
MX2021010106A (en) | Inhibitors of integrated stress response pathway. | |
MX2022005775A (en) | Therapeutic compounds and methods of use. | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
MX2021006724A (en) | Haloallylamine compounds and application thereof. | |
MX2023007853A (en) | Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof. | |
MX2020013785A (en) | Pyridopyrimidine derivative, preparation method therefor and medical use thereof. | |
NZ752750A (en) | Stable aqueous capsaicin injectable formulations and medical uses thereof | |
MX2021007453A (en) | Perineural administration of resiniferatoxin for treatment of maladaptive pain. | |
NZ757711A (en) | Antimicrobial compounds, compositions, and uses thereof | |
MX2023003627A (en) | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer. | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
MX2020014262A (en) | Pharmaceutical composition containing poorly-soluble basic medicine. | |
MX2020013692A (en) | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma. | |
MX2023000868A (en) | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof. | |
MX2020010552A (en) | Bumetanide derivatives for the therapy of hyperhidrosis. | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
MX2019013562A (en) | Fused heteroaromatic-aniline compounds for treatment of dermal disorders. | |
CR20210059A (en) | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices | |
PL423672A1 (en) | Pharmaceutical composition containing zebularine and a therapeutic agent for regeneration of wounds | |
MX2022012001A (en) | Preventative treatment of migraine. | |
MX2022006489A (en) | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof. |